Pipeline

July 1, 2019
Company Drug/Device Medical Condition Status
Cyxone T20K multiple sclerosis (MS) Phase I trial initiated enrolling healthy male volunteers in the Netherlands
NantKwest Inc. PD-L1 t-haNK solid tumors Phase I trial initiated
Pepscan clinical neoantigen peptides cancer Phase I trial initiated
I-Mab Biopharma TJC4 advanced malignant tumors Phase I trial initiated
Asieris Pharmaceuticals APL-1202 in combination with BCG (Bacillus Calmette Guerin) non-muscle invasive bladder cancer (NMIBC) Phase Ib trial initiated enrolling subjects in China
Precigen, Inc. PRGN-3006 UltraCAR-T relapsed or refractory acute myeloid leukemia (AML) or higher risk myelodysplastic syndrome (MDS) Phase I/Ib trial initiated
Syntrix Pharmaceuticals SX-682 in combination with KEYTRUDA (pembrolizumab) metastatic melanoma Phase I/II trial initiated enrolling 77 subjects at Massachusetts General Hospital and Dana Farber Cancer Institute
Minovia Therapeutics Mitochondrial Augmentation Therapy (MAT) Pearson syndrome Phase I/II trial initiated enrolling seven subjects
Xeris Pharmaceuticals, Inc. developmental ready-to-use glucagon Post-bariatric hypoglycemia (PBH) following bariatric surgery Phase II trial initiated enrolling 12 subjects with PBH
iLiAD Biotechnologies BPZE1 pertussis Phase IIb trial initiated
X4 Pharmaceuticals, Inc. mavorixafor (X4P-001) WHIM (Warts, Hypogammaglobulinemia, Infections and Myelokathexis) Phase III trial initiated enrolling 28 subjects in 20 countries
XW Laboratories Inc. XWL-008 narcolepsy Orphan Drug designation granted by the FDA
Aridis Pharmaceuticals, Inc. AR-501 lung infection associated with cystic fibrosis Orphan Drug designation granted by the FDA
LifeMax Laboratories, Inc. LM-030 Netherton Syndrome Orphan Drug designation granted by the FDA
Boehringer-Ingelheim
Eli Lilly and Company		 empagliflozin chronic heart failure Fast Track designation granted by the FDA
Arrowhead Pharmaceuticals Inc. ARO-AAT alpha-1 liver disease Fast Track designation granted by the FDA
ANI Pharmaceuticals, Inc. Vancomycin Hydrochloride for Oral Solution USP, 250 mg/5 ml enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) and antibiotic-associated pseudomembranous colitis caused by C. difficile Approval granted by the FDA
Regeneron Pharmaceuticals, Inc.
Sanofi		 Dupixent (dupilumab) chronic rhinosinusitis with nasal polyposis (CRSwNP) Approval granted by the FDA
Dignitana AB DigniCap Delta chemotherapy-induced hair loss Approval granted by the FDA

 

Upcoming Events

Featured Products

Featured Stories

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here